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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy, with an increasing incidence in western countries [1] . Overall, the prognosis is dismal, with 5-years overall survival (OS) rate after diagnosis around 10% [2] . Surgery is the only curative treatment, but most patients present with unresectable disease at the time of diagnosis [3] . In this setting, microspheres yttrium-90 selective internal radiation therapy ( 90 Y SIRT), also known as radioembolization, is being studied as a safe alternative or complement to systemic chemotherapy, with reported promising results in terms of survival and limited toxicity [4] [5] [6] [7] [8] [9] .
Response Evaluation Criteria in Solid Tumors (RECIST) is the standard method for the evaluation of response in solid tumors. RECIST is based on the change in size of target lesions [10] . Nevertheless, response to 90 Y SIRT is complex and frequently leads to necrosis without actual decrease of tumor size [11] . Therefore, RECIST may not be suitable for ICC treated with 90 Y SIRT, and have been shown to be poorly correlated with OS [12] .
Choi criteria were initially introduced to evaluate imatinib treatment in patients with gastrointestinal stromal tumors by measuring both size and density variations in the target lesions;
thus, a partial response is defined by ≥ 10% decrease in the sum of largest tumor diameter or ≥ 15% decrease in the mean of tumor density [13] . Since then, they have been evaluated for the assessment of response to various treatment modalities, including targeted therapy in hepatocellular carcinoma ( [14] ), and more importantly in patients treated with 90 Y SIRT for hepatocellular carcinoma or colorectal liver metastases [15] . They were shown to identify more responders than conventional dimension-based criteria, and to better correlate with survival. To date, no published data exist regarding their value in patients with ICC treated with 90 Y SIRT.
Therefore, the objective of this study was to compare Choi criteria with RECIST for the prediction of OS, in patients treated with 90 Y SIRT for ICC.
Materials and Methods
Study Group
Institutional review board approval was obtained for this monocentric retrospective study. A total of 45 patients were enrolled (Figure 1) . Patients' characteristics are summarized in days later during a second angiography, using glass microspheres (TheraSphere®; BTG, London, United Kingdom) with the aim of administering a dose of 120 ± 20 Gy to the injected liver volume without exceeding a dose of 30 Gy to the lungs. Calculation of the delivered dose was inferred from SPECT/CT data [17] .
Data Collection and Radiological Interpretation
Baseline clinical and biological data including tumor histology, presence of cirrhosis, previous and concomitant treatments, liver function (bilirubin, aminotransferases, albumin and prothrombin time) were extracted from medical charts. Dosimetric analyses of 90 Y SIRT procedures were also reviewed: injected activity; average absorbed dose in the tumor and in the healthy liver; and pulmonary shunt.
All images were obtained on a multi-detector-row helical CT scanner (Somatom Definition AS, Siemens, Erlangen, Germany), including at least an unenhanced acquisition on the liver and a contrast-enhanced acquisition at the portal (70 seconds) phase covering the thorax and the abdomen. A 2-mL/kg injection of iodine contrast media (300 mg/mL) with an average flow rate of 3 mL/second was performed. Slice thickness was 1.5 mm, matrix was 512 X 512.
The baseline and two first post-treatment CT were retrospectively reviewed by two radiologists (LB, 4 th year radiology resident; VB, senior radiologist with 7 years of experience in liver imaging) blinded to the clinical and follow-up data. According to RECIST 1.1 recommendations, at baseline, target lesions had to be at least ≥1 cm for the largest diameter and non-target lesions could have a largest diameter of <1 cm. A maximum of two target lesions per organ and five lesions in total were selected [10] . For each target lesion, the maximum diameter, and tumor density were measured. Tumor density was evaluated at the portal phase by selecting a polygonal region of interest encompassing the entire target lesions on the slice of the measurement of the largest diameter [18] (Figure 2 ). Although ICC may enhance on delayed acquisitions, the portal phase was used in agreement with the original method described by Choi and al. [13] . The average density of target lesions was calculated.
Response was then separately assessed according to RECIST and Choi criteria in a nonblinded fashion and the best response for each criterion among the two post treatment CT was recorded. A consensus was reached in case of disagreement. RECIST and Choi criteria are summarized in supplementary data.
A decrease in density ≥ 15% was accepted as a criterion of partial response according to Choi only if the absolute density change would account for at least 10 Hounsfield Units [18] . In case of multiple 90 Y SIRT injections, the response was evaluated on the treated lesions at the time of evaluation. Objective response (OR) was defined as the sum of complete and partial responses. We also recorded the best variations (maximal decrease or minimal increase) in the sum of target lesions diameters and their average density for each patient.
Statistical Analysis
Data were expressed as median and range, and count and rate. Continuous data were compared using the non-parametric Mann-Whitney U test, and categorical data were compared using the chi-square test or the exact Fisher's test, as appropriate. Inter-reader agreement was assessed with the Cohen's kappa statistics. Survival analyses started on the date of the first 90 Y SIRT injection. Overall survival analysis ended at the time of death or was censored at the time of the last follow-up visit. Progression-free survival ended at the time of death or progressive disease according to RECIST or was censored at the time of the last follow-up visit. Survival data were analyzed by using the Kaplan-Meier method with the log-rank test, and with a Cox regression model with univariate and multivariate analysis. All variable with a p value < 0.1 in univariate analysis were entered in the multivariate analysis, using a backward likelihood ratio method. A p value < 0.05 was considered significant.
Analysis was performed using the SPSS software package (version 19.0; SPSS, Inc., Chicago, IL).
Results
Radiological Response
The median time between the baseline pre-treatment scan and 90 Y SIRT was 17 days (range 1 Best responses as assessed by RECIST and Choi criteria are reported in Table 2 . The OR rates according to RECIST and Choi criteria were 13% (6 of 45 patients) and 82% (37 of 45), respectively. Overall, discordance between the two methods of response assessment was observed for 31 patients (69%), resulting in a kappa of 0.06 ± 0.03.
At baseline, the median size of the biggest tumor was 60 mm (range, 18 -136 mm), with a median attenuation of 73 Hounsfield Units (47 -145 HU). The maximal variations in the sum of the greatest target lesions diameters and in their average density are presented in Figure 3 .
There was no correlation between changes in size and changes in density (Pearson's correlation coefficient r = 0.09, p = 0.56).
At the time of analysis, progression was observed in 25 patients (56%). Progression was longer than that of non-responders, with a median 9.5 months (95% CI, 7.9 -11.1 months), and 2.0 months (95% CI, 1.3 -2.7 months), respectively (log-rank test: p < 0.001).
Finally, in the 39 non-responding patients according to RECIST, an objective response according to Choi criteria was associated with a better OS ( Figure 5) , with a median 19.9 months (95% CI, 5.1 -34.7 months) and 5.4 months (95% CI, 0 -11.6 months) in responders (n = 31) and non-responders (n = 8), respectively (log-rank test: p = .005).
The results of univariate and multivariate analysis of survival are given in Table 3 . If forced into the multivariate model with Choi, RECIST response was not associated with survival.
Inter-observer agreement
The kappa for inter-observer agreement was 0.71 ± 0.11 for RECIST, 0.75 ± 0.11 for Choi criteria. Disagreements in Choi criteria evaluation were observed in 4 patients (9%), due to discrepancies in density variation measurement (n = 1), the interpretation of the appearance of ascites and pleural effusion (n = 1), and the appearance of small hypodense lesions on the post therapeutic CT scan interpreted by one reader as evidence of progression due to new lesion, and by the other as response with necrosis of pre-existing lesion (n = 2). Disagreements in RECIST evaluation were observed in 6 patients (13%), due to differences in the measurement of size variation (n = 3) or by the interpretation of non-target lesions and new lesions (same cases as for Choi criteria).
Discussion
In this retrospective study of patients treated by 90 Y SIRT for ICC, we sought to compare
Choi criteria with RECIST in terms of predicting OS. We found that patients who achieved an OR according to Choi criteria had improved OS and progression-free survival as compared to non-responding patients, whereas there was no significant difference in the survival of responding and non-responding patients according to RECIST. Moreover, among the majority of patients classified as non-responders according to RECIST, the use of Choi criteria differentiated a subset of patients that benefited from 90 Y SIRT.
These results can be explained by the inability of RECIST to assess the necrotic effect of 90 Y SIRT. Tumor response assessment based on change in size may be appropriate for treatments that result in significant tumor shrinkage; however, 90 Y SIRT may cause predominant tissue necrosis [15] . Necrosis is related to avascular tissue, depicted on imaging as a lack on contrast uptake. This would be translated first by a decrease in tissue density, and only subsequently by a decrease in tumor size. This explains why variations in density were more marked in this study. In fact, decrease in greatest tumor diameters were also frequently noted, but in the majority of the cases, such decrease of size was lower than the -30% threshold for an OR according to RECIST. As a consequence, the Choi criteria, evaluating both size and density, performed better in identifying the subset of patients with a better prognosis.
We did not observe any case of complete response with both RECIST and Choi criteria, which is not surprising since it would have implied the total disappearance of all lesions, a response that is not expected at an early stage after SIRT. Only 6 among the 37 patients with partial response according to Choi criteria later experienced progression on the treated lesion.
To our knowledge, no study examining Choi criteria assessment of response to 90 Y SIRT in cholangiocarcinoma has been published to date. However, another study using alternative size-based response criteria (namely modified RECIST or the European Association for the Study of Liver (EASL)) have shown that enhancement of lesions was a valid surrogate for tissue viability in ICC treated by 90 Y SIRT [12] . Authors showed a significant lower OR rates according to RECIST (6.2%) when compared to both mRECIST (50%) and EASL criteria (56.2%). Compared to Choi criteria, mRECIST and EASL criteria have the advantage of being transposable from computed tomography to magnetic resonance imaging. On the other hand, they were introduced for hypervascular lesions, thus needing an adaptation to delayedphase imaging in cholangiocarcinoma [12] . SIRT may also induce a homogenous decrease in the density of the whole lesion, which justifies the use of a global measurement of density rather than a unidimensional measurement of the assumed viable part of the lesion. Moreover, EASL criteria only evaluate the local response to treatment [19] whereas we observed that progression was mostly extra hepatic.
Most of the discrepancies observed between the two observers were due to the appearance of small hypodense lesions on the post therapeutic CT scan whereas the density of target lesions had decreased; after consensus, these lesions were considered as small isodense lesions on the injections, several months could pass between the first and last injections. Yet, we saw that the time to progression was quite short in this population and the assessment of response after the first injection rather than at the end of treatment seems valid.
Limitations of the present study included its monocentric and retrospective design, and as a consequence the varying delay between evaluation scans which prevented any analysis of the optimal time for assessment of response to 90 Y SIRT. The 49 days median period between the first 90 Y injection and the first post-treatment scan was shorter than the average delay of 3 months chosen to assess radiological response in similar studies [8] ; this attitude is routinely performed in our institution for early evaluation of innovative treatment [10] . The use of Choi criteria for the evaluation of 90 Y SIRT-induced responses in ICC raises several concerns regarding Choi criteria. Choice of target lesion, optimal scanning time, size and position of ROI may differ according to the readers, leading to lower reproducibility [20] . This is partially due to the few initial comprehensive practical guidelines regarding application [13] .
We followed the RECIST 1.1 guidelines regarding the choice of target lesions and size measurements [10] . Regarding the density measurement, we chose a widespread, simple and reproducible method by performing an average of the densities in a ROI encompassing the whole lesion [18] . Finally, as a relatively hypodense lesion at baseline, measurements of density variations in ICC may be less reliable than in hypervascular lesions such as gastrointestinal stromal tumors or hepatocellular carcinoma, since a small absolute decrease of density may lead to a high relative variation. This is why we followed the recommendation of the German GIST imaging working group and added a minimal 10 Hounsfield Units absolute decrease to the 15% relative decrease in density to validate a PR [18] .
In conclusion, Choi criteria seem more appropriate than RECIST for the identification of patients with ICC who benefit from 90 Y SIRT. They may be used for the assessment of treatment efficacy.
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